Shandong Shanda Wit Science and Technology Co Ltd (000915) - Total Liabilities
Based on the latest financial reports, Shandong Shanda Wit Science and Technology Co Ltd (000915) has total liabilities worth CN¥573.21 Million CNY (≈ $83.88 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000915 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Shandong Shanda Wit Science and Technology Co Ltd - Total Liabilities Trend (1996–2024)
This chart illustrates how Shandong Shanda Wit Science and Technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000915 total asset value.
Shandong Shanda Wit Science and Technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Shanda Wit Science and Technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jilin Forest
SHG:600189
|
China | CN¥2.76 Billion |
|
Festi hf
IC:FESTI
|
Iceland | Ikr71.24 Billion |
|
Shenzhen Comix Group Co Ltd
SHE:002301
|
China | CN¥4.96 Billion |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
Greece | €71.78 Million |
|
Orient International Enterprise Ltd
SHG:600278
|
China | CN¥11.22 Billion |
|
Zhejiang Qianjiang Motorcycle Co Ltd
SHE:000913
|
China | CN¥4.44 Billion |
|
Logwin AG
XETRA:TGHN
|
Germany | €384.45 Million |
|
RHI MAGNESITA INDIA LIMITED
NSE:RHIM
|
India | Rs13.00 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Shandong Shanda Wit Science and Technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Shandong Shanda Wit Science and Technolo (000915) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Shanda Wit Science and Technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Shanda Wit Science and Technology Co Ltd (1996–2024)
The table below shows the annual total liabilities of Shandong Shanda Wit Science and Technology Co Ltd from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥518.50 Million ≈ $75.87 Million |
-26.10% |
| 2023-12-31 | CN¥701.65 Million ≈ $102.67 Million |
+11.55% |
| 2022-12-31 | CN¥629.03 Million ≈ $92.05 Million |
+17.35% |
| 2021-12-31 | CN¥536.03 Million ≈ $78.44 Million |
-29.44% |
| 2020-12-31 | CN¥759.72 Million ≈ $111.17 Million |
+29.80% |
| 2019-12-31 | CN¥585.32 Million ≈ $85.65 Million |
+4.72% |
| 2018-12-31 | CN¥558.92 Million ≈ $81.79 Million |
+0.46% |
| 2017-12-31 | CN¥556.37 Million ≈ $81.41 Million |
+4.40% |
| 2016-12-31 | CN¥532.89 Million ≈ $77.98 Million |
+32.78% |
| 2015-12-31 | CN¥401.35 Million ≈ $58.73 Million |
-15.04% |
| 2014-12-31 | CN¥472.42 Million ≈ $69.13 Million |
+9.45% |
| 2013-12-31 | CN¥431.63 Million ≈ $63.16 Million |
+9.04% |
| 2012-12-31 | CN¥395.83 Million ≈ $57.92 Million |
+1.41% |
| 2011-12-31 | CN¥390.33 Million ≈ $57.12 Million |
-20.16% |
| 2010-12-31 | CN¥488.86 Million ≈ $71.54 Million |
-16.15% |
| 2009-12-31 | CN¥582.99 Million ≈ $85.31 Million |
-2.32% |
| 2008-12-31 | CN¥596.85 Million ≈ $87.34 Million |
-0.48% |
| 2007-12-31 | CN¥599.73 Million ≈ $87.76 Million |
+5.09% |
| 2006-12-31 | CN¥570.70 Million ≈ $83.51 Million |
-6.24% |
| 2005-12-31 | CN¥608.70 Million ≈ $89.07 Million |
+36.78% |
| 2004-12-31 | CN¥445.01 Million ≈ $65.12 Million |
+7.12% |
| 2003-12-31 | CN¥415.43 Million ≈ $60.79 Million |
+34.86% |
| 2002-12-31 | CN¥308.04 Million ≈ $45.08 Million |
+29.02% |
| 2001-12-31 | CN¥238.76 Million ≈ $34.94 Million |
+69.51% |
| 2000-12-31 | CN¥140.86 Million ≈ $20.61 Million |
+31.26% |
| 1999-12-31 | CN¥107.31 Million ≈ $15.70 Million |
-7.75% |
| 1998-12-31 | CN¥116.33 Million ≈ $17.02 Million |
-1.98% |
| 1997-12-31 | CN¥118.68 Million ≈ $17.37 Million |
+2.51% |
| 1996-12-31 | CN¥115.78 Million ≈ $16.94 Million |
-- |
About Shandong Shanda Wit Science and Technology Co Ltd
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration s… Read more